Celldex Therapeutics Inc
Celldex Rose on Phase 2 Melanoma Data
On June 6, 2016, Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of IBB. CLDX stock rose after the company announced its Phase 2 melanoma data.
iShares Nasdaq Biotechnology ETF (IBB) Had Strong Start to April
Celldex Therapeutics (CLDX) was the top performer among IBB holdings, rising 10.6% on April 4. The other top performers include Synergy Pharmaceuticals (SGYP) and Sage Therapeutics (SAGE)
XBI Tops Biotech ETF’s for the Week Ended November 27
Sarepta Therapeutics closed at $37.4 and was trading 15.2% above the 100-day moving average price of $32.5. It has a weight of 0.8% in XBI.
Immunogen Topped the Small-Cap Stocks with High Volumes
Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.
Celldex Leads the Small-Cap Stocks in IBB
Celldex rose by 12.3%. This is the second consecutive trading session the stock gained after it presented varlilumab data at the SITC Annual Meeting 2015.